FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WESTERMARCK, J.
Right arrow Articles by KÄHÄRI, V.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WESTERMARCK, J.
Right arrow Articles by KÄHÄRI, V.-M.
(The FASEB Journal. 1999;13:781-792.)
© 1999 FASEB


Reviews

Regulation of matrix metalloproteinase expression in tumor invasion

JUKKA WESTERMARCK1 and VELI-MATTI KÄHÄRI*

MediCity Research Laboratory and Department of Medical Biochemistry, University of Turku; and
* Department of Dermatology, Turku University Central Hospital, FIN-20520 Turku, Finland

1Correspondence: University of Turku, MediCity Research Laboratory, Tykistökatu 6, FIN-20520 Turku, Finland. E-mail:jukwes{at}utu.fi


   ABSTRACT
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
Degradation of basement membranes and stromal extracellular matrix (ECM) is crucial for invasion and metastasis of malignant cells. Degradation of ECM is initiated by proteinases secreted by different cell types participating in tumor cell invasion, and increased expression or activity of every known class of proteinases (metallo-, serine-, aspartic-, and cysteine) has been linked to malignancy and invasion of tumor cells. Studies performed over the last decade have revealed that matrix metalloproteinases (MMPs) play a crucial role in tumor invasion. Expression of MMP genes is transcriptionally regulated by a variety of extracellular factors including cytokines, growth factors, and cell contact to ECM. This review will summarize the current view on the role of MMPs in tumor growth, invasion, and survival, and focus on the role of mitogen-activated protein kinases and AP-1 and ETS transcription factors in the regulation of MMP gene expression during invasion process.—Westermarck, J., Kähäri, V.-M. Regulation of matrix metalloproteinase expression in tumor invasion.


Key Words: extracellular matrix • MMPs • interleukin • tissue inhibitors • SCC


   MATRIX METALLOPROTEINASES
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
DEGRADATION OF EXTRACELLULAR matrix (ECM)2 is essential in many physiological processes, e.g., during development, growth, and repair of tissues. On the other hand, excessive proteolysis plays an important role in several pathological conditions, e.g., rheumatoid arthritis, osteoarthritis, autoimmune blistering disorders of skin, dermal photoaging, and periodontitis (1 2 3) . Tumor invasion, metastasis, and angiogenesis require controlled degradation of ECM, and increased expression of matrix metalloproteinases (MMPs) is associated with tumor invasion and metastasis of malignant tumors with different histogenetic origin (4, 5) . MMPs are a family of at least 17 human zinc-dependent endopeptidases, collectively capable of degrading essentially all ECM components (see refs 1, 3, 5 ). According to their substrate specificity and structure, members of the MMP gene family can be classified into subgroups of collagenases, stromelysins, gelatinases, membrane-type MMPs, and other MMPs (see Fig. 1 ). In general, MMPs contain a signal peptide, a propeptide, a catalytic domain with the highly conserved zinc binding site, and a hemopexin-like domain linked to the catalytic domain by a hinge region (Fig. 1) . In addition, gelatinase-A (MMP-2) and gelatinase-B (MMP-9) contain fibronectin type II inserts within the catalytic domain and MT-MMPs contain a transmembrane domain in the carboxyl-terminal end of the hemopexin-like domain (Fig. 1) . The hemopexin domain is absent in the smallest MMP, matrilysin (MMP-7). The substrate specificity of distinct MMPs has been determined by their ability to degrade different components of ECM in vitro. However, direct evidence for the proteolytic activity of MMPs in vivo is still limited.



View larger version (34K):
[in this window]
[in a new window]
 
Figure 1. Structure of human matrix metalloproteinases. Molecular weights of active and latent forms are shown (adapted from ref 1 ).

Collagenase-1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13) are the principal secreted neutral proteinases capable of initiating degradation of native fibrillar collagens of types I, II, III, and V, and apparently play a crucial role in degradation of collagenous ECM in various physiological and pathological situations (see refs 1 2 3 ). They all cleave fibrillar collagens at a specific site, resulting in generation of amino-terminal 3/4 and carboxyl-terminal 1/4 fragments, which then rapidly denature in body temperature and are further degraded by other MMPs, e.g., gelatinases (see refs 1 2 3 ). Expression of collagenase-1 (MMP-1) in vivo is seen in areas of rapid ECM remodeling both in physiological and pathological situations. MMP-1 is expressed by several types of cells including fibroblasts, keratinocytes, chondrocytes, monocytes and macrophages, hepatocytes, and a variety of tumor cells. Substrates for MMP-1 include collagens of types I, II, III, VII, VIII, X, aggrecan, serpins, and {alpha}2-macroglobulin (1 2 3) . Collagenase-2 is synthesized by polymorphonuclear leukocytes, stored in their secretory granules, and released in response to the appropriate stimulus. In addition, expression of MMP-8 has been observed in chondrocytes, synovial fibroblasts, and endothelial cells (6) . MMP-13 was originally cloned from human breast carcinoma tissue; compared with other collagenases, its substrate specificity is exceptionally wide, including fibrillar collagens of types I, II, III, and XI, basement membrane and cartilage collagen types IV and X, collagen type IX, gelatin, laminin, tenascin, aggrecan, and fibronectin (7) . Apparently due to its ability to degrade a wide range of ECM components, the physiological expression of MMP-13 is limited to situations in which rapid and effective remodeling of collagenous ECM is required, i.e., fetal bone development and postnatal bone remodeling (8, 9) . On the other hand, MMP-13 is expressed at sites of excessive degradation of collagenous ECM in osteoarthritic cartilage (9) , rheumatoid synovium (9, 10) , chronic cutaneous ulcers (11) , intestinal ulcerations (12) , and periodontitis (13) , as well as in malignant tumors such as breast carcinomas (14 15 16) , squamous cell carcinomas (SCCs) of the head/neck and vulva (17 18 19) , cutaneous basal cell carcinomas (18) , and chondrosarcomas (20) .

The stromelysin subgroup contains stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and two other MMPs with similar substrate specificities that are less closely related structurally: MMP-7 and macrophage metalloelastase (MMP-12). MMP-3 and MMP-10 are expressed by fibroblastic cells and by normal and transformed squamous epithelial cells (18, 19) . Stromelysins degrade basement membrane components, type IV collagen, nidogen, and fibronectin; both matrilysin and macrophage metalloelastase have the ability to degrade elastin (1 2 3) .

MMP-2 (72 kDa gelatinase-A) is expressed by a variety of normal and transformed cells. MMP-9 (92 kDa gelatinase-B) is produced by keratinocytes, monocytes, alveolar macrophages, PMN leukocytes, and a large variety of malignant cells. In addition to the capacity of MMP-2 and MMP-9 to degrade gelatin, laminin, and nidogen, MMP-2 has also been reported to degrade native type I collagen and proteolytically activate MMP-9 and MMP-13 (4, 21) .

The first membrane-type MMP (MT1-MMP) (MMP-14) was cloned from invasive lung cancer cells (22) and revealed a typical five-domain modular structure resembling collagenases and stromelysins; it also contains an RXXR domain susceptible to intracellular proteolytic activation by furin (23) , an additional short carboxyl-terminal transmembrane domain, and intracellular domain. Three additional MT-MMPs have been cloned: MT2-MMP (MMP-15); MT3-MMP (MMP-16), and MT4-MMP (MMP-17) (1 2 3) . Active MT1-MMP serves as a cell membrane receptor for the complex formed of latent MMP-2 (proMMP-2) and tissue inhibitor of metalloproteinases-2 (TIMP-2); at least MT1-MMP and MT2-MMP have been shown to proteolytically activate proMMP-2 at the cell surface (21) . In addition to activation of MMPs, MT1-MMP and MT2-MMP degrade type I, II, and III collagens, gelatin, fibronectin, laminin, vitronectin, and aggrecan. In vivo, MT1-MMP is expressed both in stromal fibroblasts adjacent to invasive tumor and in malignant epithelium (19, 24) .

The cDNA of stromelysin-3 (MMP-11) was cloned from invasive breast cancer tissue. The predicted structure of MMP-11 resembles that of other stromelysins and collagenases. It has not been shown to degrade any ECM component, but it degrades serine proteinase inhibitors {alpha}1-proteinase inhibitor and {alpha}1-antitrypsin (1 2 3) . Cossins et al. (25) cloned cDNA of a novel MMP from a human mammary gland, which is identical to MMP-19 cloned from liver (26) . The predicted protein structure of MMP-19 has the closest identity with MMP-1, -3, -10, and -11. However, the presence of a carboxyl-terminal arginine rich domain suggests that this MMP belongs to a new group of MMPs (19, 26) . The ability of MMP-19 to degrade native ECM components is not known. Enamelysin (MMP-20), cloned from the odontoblastic cells, is the latest member of the human MMP family (27) . The expression of enamelysin has been observed only in dental tissues, which together with its ability to degrade dental amelogenin suggests a specific role for enamelysin in the remodeling of dental enamel.

Most MMPs are secreted as latent precursors (zymogens) that are proteolytically activated in the extracellular space, with the exception of MMP-11 and MT1-MMP, which are activated prior to secretion by Golgi-associated, furin-like proteases (see refs 1 2 3 , 21 ). The activity of MMPs in extracellular space is specifically inhibited by tissue inhibitors of metalloproteinases (TIMPs), which bind to the highly conserved zinc binding site of active MMPs at molar equivalence. The TIMP gene family consists of four structurally related members, TIMP-1, -2, -3, and -4, which show 30 to 40% identity at the amino acid level and possess 12 conserved cysteine residues (28) . TIMP-1, -2, and -4 are secreted in soluble form whereas TIMP-3 is associated with ECM. TIMPs have biological effects that extend beyond their role as inhibitors of MMP activity. They induce changes in cell morphology, stimulate growth of several cell types, and are involved in steroidogenesis and germ-cell development of both sexes (see ref 28 ). TIMP-1 and -3 are antiangiogenic (28) ; TIMP-2 is also involved in activation of MMP-2 (see ref 21 ).


   EXPRESSION OF MMPs IN CANCER
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
Tumor invasion is a multistage process in which cellular motility is associated with controlled proteolysis and that involves interactions between tumor cells and the ECM. During this process, malignantly transformed cells detach from the primary tumor, migrate, and cross structural barriers, including basement membranes and surrounding stromal collagenous ECM. Degradation of stromal ECM is also considered essential in tumor-induced angiogenesis. The proposed role of MMPs in tumor invasion is mainly based on the observations of high-level expression of distinct MMPs in invasive malignant tumors (for reviews, see refs 4, 5 ), but evidence for the activity of distinct MMPs in tumor tissues in vivo is limited. However, there is recent direct evidence that MMPs play an important role in tumor invasion and progression. For example, increased expression of TIMPs by either host or tumor cells results in reduced invasion and metastatic capacity of transformed cells (29, 30) . In addition, it has been shown that MMP activity is required for increased motility of the epithelial cells (31) and for growth of metastasized tumor cells (32) . Furthermore, MMPs have been shown to play an essential role in angiogenesis and tumor cell intravasation (33, 34) , both of which are required for tumor cell growth and metastasis. Additional evidence for the role of MMPs in invasion and growth of tumors has recently been provided by MMP knockout mice. Mice lacking MMP-7 showed reduction in intestinal tumorigenesis (35) , and MMP-2-deficient mice show reduced angiogenesis and tumor progression (36) . MMP-11 knockout mice show reduced tumorigenesis in response to chemical mutagenesis (37) .

The expression of MMPs in tumors is regulated in a paracrine manner by growth factors and cytokines secreted by tumor infiltrating inflammatory cells as well as by tumor or stromal cells; recent studies have suggested continuous cross talk between tumor cells, stromal cells, and inflammatory cells during the invasion process (4, 5, 16, 19) . Accordingly, tumor cell-derived factors that increase the expression of several MMPs in stromal cells have been purified. One of these factors, EMMPRIN, was originally identified from the cell membrane of LX-1 carcinoma cells and has been shown to induce the expression of MMP-1, MMP-3, and MMP-2 by fibroblasts (38) . Furthermore, the ability of MMPs to degrade and inactivate interleukin-1ß (IL-1ß) (39) and cleave the tumor necrosis factor {alpha} (TNF-{alpha}) precursor to a biologically active form (40) , as well as the capacity of TIMP-3 to inhibit activation of TNF-{alpha} (41) , indicate that besides degrading ECM components, MMPs and TIMPs may also regulate the availability and activity of inflammatory cytokines at the site of the tumor invasion. The current view about the role of stromal component in tumor cell invasion points out that stroma actually participates in tumor progression and that stromal fibroblasts can cause tumorigenic conversion of epithelial cells (42, 43) . Evidence for the interplay between tumor cells and the stroma has also been provided from findings that in the early stages of epithelial malignancy, when the basement membrane is still intact, angiogenesis is observed in stroma (44) . In many tumors, stromal cells also actively express ECM components, e.g., type I collagen, indicating that the surrounding stromal compartment of malignant tumors is undergoing extensive tissue remodeling and that many tumors induce formation of a specific tumor stroma present both at the primary and metastatic sites (45, 46) .

As mentioned above, tumor cell invasion is a multistep process that involves tumor cells, fibroblasts, and inflammatory cells, and all these cell types have been shown to produce ECM-degrading proteases (4, 5). In vivo expression of MMPs is localized to both tumor and stromal cells at the invading margin of the tumor, providing a mechanism for highly concerted degradation of ECM (4, 5, 15, 19) . Increased expression of MMP-1 has been observed in lung carcinomas (47, 48) , squamous cell carcinomas of the head and neck (17) , and colorectal tumors, in which expression of MMP-1 correlates with poor prognosis (49) . In all these tumors the most abundant expression of MMP-1 was observed in the stromal cells, but significant expression of MMP-1 has also been observed in stromal or intratumoral endothelial cells. Expression of MMP-1 was also observed in cancer cells located at the invasive edge of head and neck squamous cell carcinoma (SCC) cells adjacent to stromal cells, whereas the expression of MMP-13 is predominantly confined to tumor cells at the invading margin; in a subset of tumors, significant expression of MMP-13 was also observed in stromal fibroblasts (17) . This is in contrast to breast carcinomas, in which MMP-13 is expressed primarily by stromal fibroblasts (15, 16) .

Both gelatinases MMP-2 and MMP-9 are abundantly expressed in various malignant tumors (4, 5, 15) . MMP-9 is mainly expressed by malignant cells, but also by inflammatory cells, including tissue macrophages and eosinophils (15, 19, 50) . Immunohistochemical analysis of the expression of MMP-2 has shown increased abundance of the immunoreactive enzyme at the neoplastic epithelium of breast, colon, and gastric adenocarcinomas; however, in contrast to the immunohistochemical results, in situ hybridizations show an increase in MMP-2 mRNA mainly in the stromal component of tumors. This discrepancy may be explained by recent findings that latent MMP-2 binds to the cell surface of malignant cells by interaction with cell membrane-associated MT1-MMP (22, 23) . Furthermore, activated MMP-2 binds to the cell surface of invasive melanoma and endothelial cells via {alpha}vß3 integrin (51) . Recent findings that both MMP-2 and MT1-MMP mRNAs are also expressed by stromal fibroblasts of human vulvar, breast, lung, and head and neck carcinomas (15, 19, 52) suggest that MT1-MMP binds to and activates MMP-2 at the cell surface of fibroblasts. In SCCs, MMP-2 and MMP-9 may also be activated by MMP-13, which in turn may be activated by MT1-MMP (19, 21) . These kinds of activation cascades may be required to ensure cooperation between tumor and stromal cells; they greatly enhance cell surface localized proteolytic activity in vivo and indicate that selective inhibition of one MMP may be sufficient to block activation cascade and ECM degradation during tumor invasion.

In summary, enhanced expression of different MMPs in cancer tissue and experimental in vitro data indicate an essential role for MMPs in tumor cell invasion. Although the expression of MMPs in malignancies has been studied widely, the specific role of distinct MMPs in the progression of cancer may be more complex than has been assumed. For example, it has recently been shown that MMP-3, MMP-7, MMP-9, and MMP-12 can generate angiostatin from plasminogen, indicating that their expression in peritumoral area may in fact serve to limit angiogenesis and thereby inhibit tumor growth and invasion in vivo (53 54 55) . This recent view about the role of stromal cells in the progression of cancer cell growth and metastasis is particularly interesting, and additional studies about the regulation of MMP gene expression and activity in in vivo malignancies are clearly needed to understand the role and regulation of MMPs in tumor cell invasion.

Although TIMPs potently inactivate MMPs in vitro, the role of TIMPs in the regulation of MMP activity and cancer progression in vivo is unclear. Earlier studies have shown decreased expression of TIMPs at the site of tumor invasion, but a positive correlation between TIMP and MMP expression and poor prognosis of malignant tumors has recently been shown (see ref 28 ). The contradictory roles of TIMPs may result from the bimodal function of TIMPs as inhibitors of MMPs, but also as key players in the cell surface-targeted MMP activation cascades (28) . Another aspect to the role of TIMPs and MMPs in tumor growth is the observation that overexpression of TIMP-3 can induce apoptosis in normal and malignant cells (30, 56, 57) , providing evidence that MMP activity in general may be important not only for invasion, but also for the survival of malignant cells.


   REGULATION OF MMP GENE EXPRESSION
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
Expression of most MMPs is normally low in tissues and is induced when remodeling of ECM is required. MMP gene expression is primarily regulated at the transcriptional level, but there is also evidence about modulation of mRNA stability in response to growth factors and cytokines (see refs 5, 42, 43 ). The promoter regions of inducible MMP genes (MMP-1, MMP-3, MMP-7, MMP-9, MMP-10, MMP-12, MMP-13) show remarkable conservation of regulatory elements (Fig. 2 ), and their expression is induced by growth factors, cytokines, and other environmental factors such as contact to ECM (1 2 3, 58, 59) . Increased expression of other MMPs, the promoter regions of which do not contain conserved cis elements (MMP-2, MMP-11), has also been observed in malignancies, indicating overlapping mechanisms in the regulation of the expression of these genes.



View larger version (44K):
[in this window]
[in a new window]
 
Figure 2. Regulatory elements of promoter regions of human MMP genes. Modified from ref 59 . Boxes indicate the following cis elements: AP-1, activator protein-1; PEA3, polyoma enhancer A binding protein-3; TIE, TGF-ß inhibitory element; GC, Sp-1 binding site; SBE, STAT binding element; C/EBP-ß, CCAAT/enhancer binding protein-ß; OSE-2, osteoblast-specific element-2; SPRE, stromelysin-1 PDGF-responsive element; TRF, octamer binding protein; Sil, silencer sequence; NF-{kappa}B, nuclear factor-{kappa}B; NF-1, nuclear factor-1; RARE, retinoic acid responsive element.

Role of AP-1 transcription factors in the regulation of MMP gene expression
A single AP-1 element, which binds members of the AP-1 transcription factor family, is found at approximately -70 in the promoter region of each inducible MMP gene (Fig. 2) . AP-1 transcription factors are leucine zipper proteins that bind to a consensus DNA sequence (5'-TGAG/CTCA-3') as a dimeric complex (60, 61) . Three distinct members of the Jun family (c-Jun, JunB, and JunD) and four members of the Fos family (cFos, Fra-1, Fra-2, and FosB) have been characterized. Members of the Jun family can bind to DNA either as Jun/Jun homodimers or Jun/Fos heterodimers, whereas Fos proteins do not form homodimers and bind DNA in the absence of Jun (60, 61) . Different AP-1 dimers bind DNA with different affinities, which is thought to be at least partly responsible for the diverse biological effects of distinct AP-1 complexes.

The proximal AP-1 element located between -72 and -66 plays a major role in the transcriptional regulation of MMP-1 gene expression, as shown by the results that mutation of this element dramatically reduces the basal activity and responsiveness of the MMP-1 promoter to external stimuli (62 63 64) . Although the importance of additional AP-1 elements found in the promoters of MMP-1, -3, and -9 is not clear, it has been shown that in the rabbit MMP-1 promoter, they bind Fos and Jun containing AP-1 dimers and partially mediate the effect of phorbol ester (59) . Several cotransfection studies have shown that overexpression of Jun and Fos proteins enhance MMP-1 promoter activity and, in contrast, that expression of antisense mRNAs for c-jun abrogates the induction of MMP-1 gene expression. Furthermore, it has been shown that simultaneous induction of c-jun and junB mRNAs precedes induction of MMP-1 gene expression by several types of stimuli (for references, see refs 1, 58, 59 ). c-Jun is capable of inducing the minimal MMP-1 promoter activity as a Jun/Jun homodimer, whereas induction of minimal (76 bp) MMP-1 promoter by JunB requires the presence of several AP-1 elements or simultaneous expression of c-Fos (65, 66) . However, in HT-1080 fibrosarcoma cells, in which c-Jun expression is not induced by tumor promoter okadaic acid, JunB containing AP-1 complexes mediate the activation of the full-length (3.8 kb) MMP-1 promoter (67) . We have also observed that in NIH-3T3 fibroblasts, in which overexpression of JunB alone does not stimulate minimal MMP-1 promoter, JunB is a potent activator of full-length MMP-1 promoter (64) . These findings indicate that c-Jun is an independent activator of MMP-1 gene expression, whereas trans-activation of MMP-1 promoter by JunB, and possibly by other AP-1 transcription factors, is dependent on the interaction with other transcription factors binding to additional regulatory cis-elements in the 5'-flanking region of the MMP-1 gene.

Recent studies with c-Fos knockout mice reveal that c-Fos is required for malignant and invasive progression of skin papillomas and for induction of mouse MMP-3 and MMP-13 gene expression by platelet-derived growth factors and epidermal growth factor, but not by phorbol ester (68, 69) . In addition, overexpression of c-Fos in transgenic mice under an interferon-inducible promoter was shown to induce expression of mouse MMP-13 in thymus, spleen, and predominantly in bone, revealing that the capacity of c-Fos to activate mouse MMP-13 gene expression in vivo is cell type specific (70) . The finding that neither mouse MMP-9, MMP-3, nor MMP-10 expression was affected by c-Fos overexpression suggests that c-Fos differently regulates expression of distinct MMP genes in vivo and that the AP-1 element alone does not determine the inducibility of the MMP promoter by c-Fos in vivo (70) .

Little is known about the regulation of AP-1 activity in malignant tumors in vivo. Increased expression of AP-1 genes has been reported during growth of malignant tumors, but there is no consistent pattern of AP-1 complexes that would serve as a marker for increased invasion or malignancy. Decreased expression of c-jun, junB, and c-fos genes was observed in human lung carcinomas as compared with normal tissue (71) . As the expression of different AP-1 components at sites of MMP expression during tumor invasion is not known, determination of the specific AP-1 complex pattern responsible for induction of MMP gene expression in vivo would be important in developing specific approaches to prevent tumor invasion and metastasis.

ETS transcription factors in the regulation of MMP expression
Conserved PEA3 elements that bind members of ETS transcription factors have also been found in all inducible MMP promoters; with the exception of the MMP-12 promoter, they are located adjacent to at least one AP-1 element (Fig. 2) . ETS transcription factors are helix-turn-helix proteins that share a modular domain structure characterized by a highly conserved ETS domain, which recognizes the purine rich PEA3 element A/CGGAA/T (72) . Although ETS proteins have been shown to trans-activate artificial promoter constructs containing only the PEA3 element, ETS proteins do not usually dimerize and bind to DNA alone, but prefer to form complexes with other transcription factors, e.g., AP-1, for which they function as coactivators (72, 73) .

Expression of ETS-1 colocalizes with several MMPs to the stromal fibroblasts adjacent to the invasive edge of several types of tumors (47, 48, 74) . ETS-1 expression has also been detected during angiogenesis in human embryos, in granulation tissue, and during tumor vascularization (75) . Furthermore, overexpression of the ETS-related transcription factor E1A-F, which activates MMP-1, MMP-3, and MMP-9 promoters, has been shown to induce an invasive phenotype in MCF-7 cells (76) . In addition, overexpression of ETS-1, ETS-2, and PEA3 enhances the activity of full-length MMP-1, MMP-3 and MMP-9 promoters (64, 77, 78) . The functional interplay between AP-1 and ETS factors in the regulation of MMP gene expression has been recently shown by us and others. Our results indicate that expression of structurally distinct ETS factors (ETS-1, ERGB/Fli-1, PU.1) differentially modulate AP-1-dependent MMP-1 promoter activation (64) . ETS-1 markedly enhanced the stimulation of MMP-1 promoter by both c-Jun and JunB, whereas ERGB/Fli-1 alone does not regulate MMP-1 gene expression and potentiates only the effect of c-Jun. In contrast, PU.1 overexpression potently blocked activation of MMP-1 promoter by overexpression of c-Jun and JunB or by stimulation by phorbol ester and okadaic acid (64) . ETS factor Erg was recently shown to physically interact and cooperate with Jun/Fos in the up-regulation of MMP-1 promoter activity (61) . These results indicate that in vivo interactions between distinct transcription factors may modulate the response of MMP promoters in situations where simultaneous induction of the expression of both ETS and AP-1 factors occurs, such as tumor cell growth and invasion.


   MITOGEN-ACTIVATED PROTEIN KINASES
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
DNA binding and trans-activation capacity of both AP-1 and ETS transcription factors are regulated by phosphorylation by mitogen-activated protein kinases (MAPKs), serine/threonine kinases that mediate signals from cell membrane receptors triggered by growth factors, cytokines, hormones, and cell-cell and cell-matrix interactions (for reviews, see refs 79 80 81 ). Three MAPK pathways have been characterized in detail (see Fig. 3 ). The ERK1,2 pathway (Ras->Raf->MEK1,2->ERK1,2) is activated by a large variety of mitogens and by phorbol esters, whereas the JNK/SAPK (MEKK1–4->MKK4/MKK7->JNK/SAPKs) and p38 (TAK1->MKK3/MKK6->p38s) pathways are mainly stimulated by environmental stress and inflammatory cytokines (Fig. 4 ). Other stress-activated MAPKs, including ERK5 and ERK6, have been characterized recently (80, 81) .



View larger version (35K):
[in this window]
[in a new window]
 
Figure 3. Schematic presentation of MAPK pathways. For details, see refs 80, 81 . Kinases of ERK1,2, JNK/SAPK, and p38 pathways are underlined.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 4. Targets for inhibiting MMP expression and activity

It is thought that the balance between distinct MAPK pathways regulates cell growth, differentiation, survival, and death. Constitutively active mutants of Raf-1 and MEK1 have been shown to transform fibroblasts in vitro (82, 83) , and in vivo activation of ERK1/2 pathway has been observed in renal and breast carcinomas (84, 85) . Furthermore, the full transformation capacity of oncogenic Ras has been shown to require activation of stress-activated MAPKs, indicating functional interplay between mitogen and stress-activated MAPK pathways during the transformation process (86) .

Transcriptional activity and c-Jun protein stability is increased by phosphorylation of serines 63 and 73 by JNK/SAPK, whereas phosphorylation of threonines 91 and 93 leads to enhanced c-Jun DNA binding (see ref 79 ). Activation of ERK1,2 was recently shown to induce c-Jun expression and phosphorylation, indicating cross talk between ERK1,2 and JNK/SAPK pathways in the regulation of c-Jun activity (87) . Although p38 MAPK does not directly phosphorylate c-Jun, it contributes to enhanced AP-1 activity by activation of transcription factors (ATF-2, MEF2C, Elk-1, SAP-1) that up-regulate c-jun and c-fos promoter activities (79) . Phosphorylation of c-Fos by p90rsk and ERK2 stabilizes the c-Fos protein and results in increased trans-activation and transformation capacity of c-Fos. Furthermore, the activity and DNA binding of ETS transcription factors SAP-1 and Elk-1, which participate in c-fos promoter activation through serum responsive element, is regulated by ERK1,2, JNK/SAPK, and p38 pathways (80, 81, 88) . Activation of Ras has been shown to trans-activate ETS-1 and ETS-2, and ERK1,2 and JNK/SAPK pathways have been shown to coordinately mediate activation of ETS factor PEA3 by Ras (89) .

Taken together, both AP-1 and ETS transcription factors are subject to regulation by mitogen- and stress-activated MAPK signaling pathways. Recent identification of specific adapter proteins that physically connect kinases of MAPK cascades suggests the existence of highly specific MAPK cascades that are activated in specific situations (90, 91) . These signal transduction cascades allow strict control of amplification, feedback, cross talk, and branching of the initial signals triggered from the cell membrane resulting in a precise regulation of gene expression in situations such as tumor cell invasion.

Role of MAPKs in the regulation of MMP gene expression
As discussed, the role of phosphorylation in the regulation of the AP-1 and ETS transcription factors is fairly well established. However, the role of distinct phosphorylation-dependent signaling pathways in the regulation of MMP gene expression has been determined only recently. Increased serine/threonine phosphorylation as a result of inhibition of serine/threonine phosphatase PP2A by tumor promoter okadaic acid induces expression of MMP-1 and MMP-3 at transcriptional level (67, 92) . Evidence for the role of MAPKs in the transcriptional regulation of MMP gene expression was shown by results indicating that blocking the ERK pathway abrogated Ras, serum, and TPA-elicited induction of a minimal promoter construct containing 72 bp of MMP-1 promoter, harboring the proximal AP-1 element (93) . Furthermore, overexpression of dominant negative MEK was shown to block insulin-elicited induction of a reporter construct under the control of an AP-1 element from the MMP-1 promoter (94) . Recently, overexpression of dominant negative Raf-1 was shown to block oncostatin M elicited induction of a promoter construct containing copies of oligonucleotides encompassing the AP-1 and an earlier unidentified STAT binding site of the MMP-1 promoter in front of a heterologous promoter (95) . Protein kinase C (PKC) has been shown to activate ERK1,2 signaling pathway, and it was recently shown that selective overexpression of PKC isoforms PKC{delta}, PKC{epsilon}, and PKC{zeta} activate the full-length MMP-1 promoter (96) . Taken together, these recent results indicate that mitogen-activated ERK1,2 pathway would be the major activator of MMP-1 gene expression.

In normal skin fibroblasts, enhancement of MMP-1 expression by TNF and the IL-1-induced lipid second messenger ceramide is mediated by coordinate activation of ERK1,2, JNK/SAPK, and p38 MAPK pathways (97) . Our recent results also show that activity of ERK1,2, JNK/SAPK, and particularly p38, is required for induction of MMP-1 expression and promoter activity by the tumor promoter okadaic acid (98) . The involvement of stress-activated MAPK pathways in the regulation of MMP gene expression is also supported by findings that inhibition of p38 activity by specific chemical inhibitor SB 203580 blocks the IL-1 elicited induction of MMP-1 and MMP-3 expression in human fibroblasts and vascular endothelial cells (99) . Further evidence for the importance of stress-activated pathways in migration and invasion of fibroblasts is provided in our findings showing that induction of MMP-13 expression by contact to 3-dimensional collagen is dependent on the activity of p38 MAPK (100) .

The role of MAPKs in regulation of MMP expression has also been examined in malignant cells. In addition to MMP-1 and MMP-3, increased transcriptional activity of the MMP-9 promoter in Ras-transformed OVCAR-3 cells was shown to be mediated by MAP kinases, but blocking the ERK pathway was not sufficient to abrogate the signal, suggesting a role for stress-activated MAPK pathways as mediators of effect of Ras (78) . On the other hand, induction of MMP-9 promoter activity by oncogenic Ras in SCC cells was abrogated by blocking either the ERK1,2 or JNK/SAPK pathways, indicating cell-specific differences in the role of distinct MAPKs in the regulation of MMP promoter activity (101) . The first evidence for the role of MAPKs in the regulation of cancer cell invasion was recently demonstrated by showing that inhibition of p38 activity by SB 203580 blocks phorbol ester-elicited induction of MMP-9 expression by SCC cells as well as their invasion through Matrigel (102) .

Taken together, these results indicate cooperation of multiple MAPK pathways in the regulation of MMP transcription in response to different signals. In addition to growth factors and cytokines, invasive cancer cells and stromal cells at the invading edge of the tumor are under physical stress, such as hypoxia and hyperthermia. Based on the current view on the importance of stress-activated MAPKs in the regulation of MMP expression, it could be assumed that activation of AP-1 and ETS transcription factors by these MAPKs is responsible for maximal activation of MMP expression in stress conditions present in the tumor and that, in addition to its role in the gene regulation, activation of ERK1,2 pathway may be important for survival of cancer cells by protecting them from the programmed cell death caused by stress-induced JNK/SAPK activation (103, 104) . It will be of great interest to determine whether invasion specific MAPK –> AP-1/ETS routes exists in vivo and whether inhibition of these pathways could serve as a therapeutic target to specifically prevent tumor cell invasion and metastasis.


   MMPs AS TARGETS TO INHIBIT TUMOR CELL INVASION
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 
As discussed, MMP expression during cancer cell invasion is regulated by multiple extracellular factors including cytokines, growth factors, and interactions with adjacent cells and ECM. Every level of regulation of MMP expression and activity can be considered as a target for therapeutic intervention (see Fig. 4 ). In this respect, it is important to understand the mechanisms of the regulation of MMP expression in malignant tumors in vivo. For example, it was recently shown that overexpression of transforming growth factor ß (TGF-ß) under keratin 6 promoter inhibited formation of benign skin tumors in transgenic mice but enhanced progression to invasive carcinomas in mouse skin multistage carcinogenesis model (105) , indicating that different cell populations may alter their response to factors such as TGF-ß. Furthermore, detailed characterization of growth factor and cytokine receptors responsible for activation of signaling pathways would help in designing receptor antagonists and neutralizing antibodies to prevent the action of these factors. For example, we have previously shown that TNF-{alpha} stimulates MMP-1 expression in fibroblasts through 55 kDa TNF receptor (106) , suggesting targeting of this receptor pathway, as has been shown in organ cultures (107)

Regarding inhibition of MMP expression at the level of kinase pathways, it is possible that selective chemical inhibitors for distinct signaling pathways (e.g., MAPK, PKC) will soon be available for initial clinical trials. It is therefore important to identify growth and/or invasion specific signaling cascades that could serve as targets for chemical inhibitors or dominant negative kinase mutants and antisense oligonucleotides (108) . Overexpression of selective dual-specificity MAPK phosphatases shown to prevent MMP promoter activation (97, 98, 101) could also be used as a novel strategy to prevent activation of AP-1 and ETS transcription factors and MMP promoters in vivo.

Interactions between members of different transcription factors increases capability of fine-tuning the transcriptional regulation of MMP promoter activity. It is possible that constitutive expression of specific transcription factors as a result of transformation may modulate the response of MMP promoter to extracellular signals. For example, overexpression of several ETS factors has been observed in hematological malignancies as a result of proviral insertion into the ETS gene or by chromosomal translocation, possibly resulting in potentiation of AP-1 induced up-regulation of MMP expression, as shown recently in vitro (64, 77) . It was recently shown that peritoneally injected, double-stranded AP-1 oligomers potently prevent AP-1 dependent activation of MMP gene expression in mouse arthrosis model (109) , indicating that it is possible to block transcriptional activation of MMP gene expression in vivo by eliminating binding of the transcription factors. Also, novel retinoids that potently inhibit cell proliferation have been shown to selectively abrogate AP-1 dependent gene expression (110) . Besides the treatment strategies targeted to inhibit MMP promoter activation, degradation of MMP mRNA by antisense RNA or ribozyme techniques may also provide efficient and specific tool to prevent tumor cell invasion as shown in vitro and in vivo (111, 112) .

Inactivation of MMPs in pericellular space by either overexpression of TIMPs or synthetic MMP inhibitors may prevent initiation of MMP activation cascades and excessive ECM degradation. Several small molecule MMP inhibitors are currently in phase I/II clinical trials, and a hydroxamate MMP inhibitor, marimastat, is already entering phase III trials in a number of solid tumors (113, 114) . Although initially aimed at inhibiting tumor invasion and metastasis and inhibiting tumor growth by inhibiting angiogenesis, it is possible that MMP inhibitors also directly inhibit tumor growth, as inhibition of MMP activity by TIMP-3 and tetracyclines has been shown to induce apoptosis in malignant cells (30, 56, 57, 115) .


   ACKNOWLEDGMENTS
 
The original work of authors cited here has been supported by grants from the Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation of Finland, Foundation for The Finnish Cancer Institute, and Turku University Central Hospital.


   FOOTNOTES
 
2 Abbreviations: ECM, extracellular matrix; IL, interleukin; MAPK, mitogen-activated protein kinase; MMPs, matrix metalloproteinases; MMP-1, collagenase-1; MMP-2, gelatinase-A; MMP-3, stromelysin-1; MMP-7, matrilysin; MMP-8, collagenase-2; MMP-9, gelatinase-B; MMP-10, stromelysin-2; MMP-11, stromelysin-; MMP-12, metalloelastase; MMP-13, collagenase-3; MMP-20, enamelysin; PKC, protein kinase C; SCC, squamous cell carcinoma; TGF, transforming growth factor; TIMPs, tissue inhibitors of metalloproteinases; TNF, tumor necrosis factor.


   REFERENCES
TOP
ABSTRACT
MATRIX METALLOPROTEINASES
EXPRESSION OF MMPs IN...
REGULATION OF MMP GENE...
MITOGEN-ACTIVATED PROTEIN...
MMPs AS TARGETS TO...
REFERENCES
 

  1. Kähäri, V.-M., Saarialho-Kere, U. (1997) Matrix metalloproteinases in skin. Exp. Dermatol. 6,199-213[Medline]
  2. Shapiro, S. D. (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10,602-608[Medline]
  3. Woessner, J. F. (1998) The matrix metalloproteinase family. Parks, W. C. Mecham, R. P. eds. Matrix Metalloproteinases ,1-14 Academic Press San Diego.
  4. Basset, P., Okada, A., Chenard, M.-P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J.- P., Rio, M.-C. (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutical implications. Matrix Biol 15,535-541[Medline]
  5. Johnsen, M., Lund, L. R., Romer, J., Almholt, K., Danø, K. (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 10,667-671[Medline]
  6. Hanemaaijer, R., Sorsa, T., Konttinen, Y. T., Ding, Y., Sutinen, M., Visser, H., van Hinsbergh, V. W., Helaakoski, T., Kainulainen, T., Ronka, H., Tschesche, H., Salo, T. (1997) Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-{alpha} and doxycycline. J. Biol. Chem. 272,31504-31509[Abstract/Free Full Text]
  7. Knäuper, V., Cowell, S., Smith, B., López-Otín, C., O'Shea, M., Morris, H., Zardi, L., Murphy, G. (1997) The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J. Biol. Chem. 272,7608-7616[Abstract/Free Full Text]
  8. Johansson, N., Saarialho-Kere, U., Airola, K., Herva, R., Nissinen, L., Westermarck, J., Vuorio, E., Heino, J., Kähäri, V.-M. (1997) Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev. Dyn. 208,387-397[Medline]
  9. Ståhle-Bäckdahl, M., Sandstedt, B., Bruce, K., Lindahl, A., Jimenez, M. G., Vega, J. A., López-Otín, C. (1997) Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab. Invest. 76,717-728[Medline]
  10. Lindy, O., Konttinen, Y. T., Sorsa, T., Ding, Y., Santavirta, S., Ceponis, A., López-Otín, C. (1997) Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arth. Rheum. 40,1391-1399[Medline]
  11. Vaalamo, M., Mattila, L., . Johansson. N., Kariniemi. A.-L., Karjalainen-Lindsberg. M.-L.,Kähäri, V.-M., Saarialho-Kere, U (1997) Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J. Invest. Dermatol. 109,96-101[Medline]
  12. Vaalamo, M., Karjalainen-Lindsberg, M. L., Puolakkainen, P., Kere, J., Saarialho- Kere, U. (1998) Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am. J. Pathol. 152,1005-1014[Abstract]
  13. Uitto, V.-J., Airola, K., Vaalamo, M., Johansson, N., Putnins, E., Firth, J. D., Salonen, J., López-Otín, C., Saarialho-Kere, U., Kähäri, V.-M. (1998) Collagenase-3 (matrix metalloproteinase-3) expression is induced in oral mucosal epithelium during chronic inflammation. Am. J. Pathol. 152,1489-1499[Abstract]
  14. Freije, J. M., Díez-Itza, I., Balbín, M., Sánchez, L. M., Blasco, R., Tolivia, J., López-Otín, C. (1994) Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269,16766-16773[Abstract/Free Full Text]
  15. Heppner, K. J., Matrisian, L. M., Jensen, R. A., Rodgers, W. H. (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149,273-282[Abstract]
  16. Uría, J. A., Ståhle-Bäckdahl, M., Seiki, M., Fueyo, A., López-Otín, C. (1997) Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 57,4882-4888[Abstract/Free Full Text]
  17. Johansson, N., Airola, K., Grénman, R., Kariniemi, A.-L., Saarialho-Kere, U., Kähäri, V.-M. (1997) Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol. 151,499-508[Abstract]
  18. Airola, K., Johansson, N., Kariniemi, A.-L., Kähäri, V.-M., Saarialho-Kere, U. (1997) Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J. Invest. Dermatol. 109,225-231[Medline]
  19. Johansson, N., Vaalamo, M., Grénman, S., Hietanen, S., Klemi, P., Saarialho-Kere, U., Kähäri, V.-M. (1999) Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol. 154,469-480[Abstract/Free Full Text]
  20. Uría, J. A., Balbín, M., López, J. M., Alvarez, J., Vizoso, F., Takigawa, M., López-Otín, C. (1998) Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am. J. Pathol. 153,91-101[Abstract/Free Full Text]
  21. Murphy, G., Knäuper, V. (1997) Relating matrix metalloproteinase structure to function: why the `hemopexin' domain?. Matrix Biol 15,511-518[Medline]
  22. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (London) 370,61-65[Medline]
  23. Sato, H., Kinoshita, T., Takino, T., Nakayama, K., Seiki, M. (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393,101-104[Medline]
  24. Gilles, C., Polette, M., Seiki, M., Birembaut, P., Thompson, E. (1997) Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab. Invest. 76,651-660[Medline]
  25. Cossins, J., Dudgeon, T. J., Catlin, G., Gearing, A. J., Clements, J. M. (1996) Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem. Biophys. Res. Commun. 228,494-498[Medline]
  26. Pendas, A. M., Knäuper, V., Puente, X. S., Llano, E., Mattei, M. G., Apte, S., Murphy, G., López-Otín, C. (1997) Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J. Biol. Chem. 272,4281-4286[Abstract/Free Full Text]
  27. Llano, E., Pendas, A., Knäuper, V., Sorsa, T., Salo, T., Salido, E., Murphy, G., Simmer, J., Bartlett, J., López-Otín, C. (1997) Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 36,15101-15108[Medline]
  28. Gomez, D. E., Alonso, D. F., Yoshiji, H., Thorgeirsson, U. P. (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74,111-122[Medline]
  29. Kruger, A., Sanchez Sweatman, O. H., Martin, D. C., Fata, J. E., Ho, A. T., Orr, F. W., Ruther, U., Khokha, R. (1998) Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16,2419-2423[Medline]
  30. Ahonen, M., Baker, A., Kähäri, V.-M. (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinaises-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58,2310-2315[Abstract/Free Full Text]
  31. Pilcher, B., Dumin, J., Sudbeck, B., Krane, S., Welgus, H., Parks, W. C. (1997) The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J. Cell Biol. 137,1445-1457[Abstract/Free Full Text]
  32. Koop, S., Khokha, R., Schmidt, E. E., MacDonald, I. C., Morris, V. L., Chambers, A. F., Groom, A. C. (1994) Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54,4791-4797[Abstract/Free Full Text]
  33. Kim, J., Yu, W., Kovalski, K., Ossowski, L. (1998) Requirement of specific proteases in cancer cell intravasation as revealed by novel semiquantitative PCR-based assay. Cell 94,353-362[Medline]
  34. Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., Cheresh, D. A. (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92,391-400[Medline]
  35. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L., Matrisian, L. M. (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. U. S. A. 94,1402-1407[Abstract/Free Full Text]
  36. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., Itohara, S. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58,1048-1051[Abstract/Free Full Text]
  37. Masson, R., Lefebvre, O., Noel, A., Fahime, M. E., Chenard, M. P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J. M., Basset, P., Rio, M. C. (1998) In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140,1535-1541[Abstract/Free Full Text]
  38. Guo, H., Zucker, S., Gordon, M. K., Toole, B. P., Biswas, C. (1997) Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J. Biol. Chem. 272,24-27[Abstract/Free Full Text]
  39. Ito, A., Mukaiyama, A., Itoh, Y., Nagase, H., Thogersen, I. B., Enghild, J. J., Sasaguri, Y., Mori, Y. (1996) Degradation of interleukin-1ß by matrix metalloproteinases. J. Biol. Chem. 271,14657-14660[Abstract/Free Full Text]
  40. Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J.-L., Warner, J., Willard, D., Becherer, J. D. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-{alpha}. Nature (London) 385,733-736[Medline]
  41. Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knäuper, V., Docherty, A. J. P., Murphy, G. (1998) TNF-{alpha} converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435,39-44[Medline]
  42. Atula, S., Grenman, R., Syrjänen, S. (1997) Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp. Cell Res. 235,180-187[Medline]
  43. Skobe, M., Fusenig, N. E. (1998) Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. U. S. A. 95,1050-1055[Abstract/Free Full Text]
  44. Hanahan, D., Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86,353-364[Medline]
  45. Iozzo, R. V. (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab. Invest. 73,157-160[Medline]
  46. Kauppila, S., Saarela, J., Stenbäck, F., Risteli, J., Kauppila, A., Risteli, L. (1996) Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Am. J. Pathol. 148,539-548[Abstract]
  47. Bolon, I., Gouyer, V., Devouassoux, M., Vandenbunder, B., Wernert, N., Moro, D., Brambilla, C., Brambilla, E. (1995) Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am. J. Pathol. 147,1298-1310[Abstract]
  48. Bolon, I., Brambilla, E., Vandenbunder, B., Robert, C., Lantuejoul, S., Brambilla, C. (1996) Changes in the expression of matrix proteases and of the transcription factor c- Ets-1 during progression of precancerous bronchial lesions. Lab. Invest. 75,1-13[Medline]
  49. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., Fothergill, J. E. (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2,461-462[Medline]
  50. Ståhle-Bäckdahl, M., Parks, W. C. (1993) 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am. J. Pathol. 142,995-1000[Abstract]
  51. Brooks, P. C., Stromblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., Cheresh, D. A. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin {alpha}vß3. Cell 85,683-693[Medline]
  52. Polette, M., Nawrocki, B., Gilles, C., Sato, H., Seiki, M., Tournier, J. M., Birembaut, P. (1996) MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428,29-35[Medline]
  53. Patterson, B. C., Sang, Q. A. (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272,28823-28825[Abstract/Free Full Text]
  54. Lijnen, H. R., Ugwu, F., Bini, A., Collen, D. (1998) Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37,4699-4702[Medline]
  55. Dong, Z., Kumar, R., Yang, X., Fidler, I. J. (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88,801-810[Medline]
  56. Baker, A. H., Zaltsman, A. B., George, S. J., Newby, A. C. (1998) Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis. J. Clin. Invest. 101,1478-1487[Medline]
  57. Bian, J., Wang, Y., Smith, M. R., Kim, H., Jacobs, C., Jackman, J., Kung, H. F., Colburn, N. H., Sun, Y. (1996) Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17,1805-1811[Abstract/Free Full Text]
  58. Vincenti, M. P., White, L. A., Schroen, D. J., Benbow, U., Brinckerhoff, C. E. (1996) Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit. Rev. Eukaryot. Gene Exp. 6,391-411[Medline]
  59. Benbow, U., Brinckerhoff, C. (1997) The AP-1 site and MMP gene regulation: What is all the Fuss about?. Matrix Biol 15,519-526[Medline]
  60. Karin, M., Liu, Z.-G., Zandi, E. (1997) AP-1 function and regulation. Curr. Opin. Cell Biol. 9,240-246[Medline]
  61. Angel, P., Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta 1072,129-157[Medline]
  62. Lee, J. S., See, R. H., Deng, T., Shi, Y. (1996) Adenovirus E1A downregulates cJun- and JunB-mediated transcription by targeting their coactivator p300. Mol. Cell. Biol. 16,4312-4326[Abstract]
  63. Doyle, G. A. R., Pierce, R. A., Parks, W. C. (1997) Transcriptional induction of collagenase-1 in differentiated monocyte-like (U937) cells is regulated by AP-1 and an upstream C/EBP-ß site. J. Biol. Chem. 272,11840-11849[Abstract/Free Full Text]
  64. Westermarck, J., Seth, A., Kähäri, V.-M. (1997) Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 14,2651-2660[Medline]
  65. Chiu, R., Angel, P., Karin, M. (1989) Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell 59,979-986[Medline]
  66. Bergelson, S., Daniel, V. (1994) Cooperative interaction between Ets and AP-1 transcription factors regulates induction of glutathione S-transferase Ya gene expression. Biochem. Biophys. Res. Commun. 200,290-297[Medline]
  67. Westermarck, J., Lohi, J., Keski-Oja, J., Kähäri, V.-M. (1994) Okadaic acid-elicited transcriptional activation of collagenase gene expression in HT-1080 fibrosarcoma cells is mediated by JunB. Cell Growth Differ 5,1205-1213[Abstract]
  68. Hu, E., Mueller, E., Oliviero, S., Papaioannou, V. E., Johnson, R., Spiegelman, B. M. (1994) Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J 13,3094-3103[Medline]
  69. Saez, E., Rutberg, S. E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S. H., Spiegelman, B. M. (1995) c-fos is required for malignant progression of skin tumors. Cell 82,721-732[Medline]
  70. Gack, S., Vallon, R., Schaper, J., Ruther, U., Angel, P. (1994) Phenotypic alterations in fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein. J. Biol. Chem. 269,10363-10369[Abstract/Free Full Text]
  71. Levin, W. J., Press, M. F., Gaynor, R. B., Sukhatme, V. P., Boone, T. C., Reissmann, P. T., Figlin, R. A., Holmes, E. C., Souza, L. M., Slamon, D. J. (1995) Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 11,1261-1269[Medline]
  72. Sharrocks, A. D., Brown, A. L., Ling, Y., Yates, P. R. (1997) The ETS-domain transcription factor family. Int. J. Biochem. Cell Biol. 12,1371-1387
  73. Carrere, S., Verger, A., Flourens, A., Stehelin, D., Duterque-Coquillaud, M. (1998) Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 16,3261-3268[Medline]
  74. Wernert, N., Gilles, F., Fafeur, V., Bouali, F., Raes, M. B., Pyke, C., Dupressoir, T., Seitz, G., Vandenbunder, B., Stehelin, D. (1994) Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 54,5683-5688[Abstract/Free Full Text]
  75. Wernert, N., Raes, M. B., Lassalle, P., Dehouck, M. P., Gosselin, B., Vandenbunder, B., Stehelin, D. (1992) c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. 140,119-127[Abstract]
  76. Kaya, M., Yoshida, K., Higashino, F., Mitaka, T., Ishii, S., Fujinaga, K. (1996) A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 12,221-227[Medline]
  77. Buttice, G., Duterque Coquillaud, M., Basuyaux, J. P., Carrere, S., Kurkinen, M., Stehelin, D. (1996) Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13,2297-2306[Medline]
  78. Gum, R., Lengyel, E., Juarez, J., Chen, J. H., Sato, H., Seiki, M., Boyd, D. (1996) Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271,10672-10680[Abstract/Free Full Text]
  79. Minden, A., Karin, M. (1997) Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1333,F85-F104[Medline]
  80. Robinson, M. J., Cobb, M. H. (1997) Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9,180-186[Medline]
  81. Lewis, T. S., Shapiro, P. S., Ahn, N. G. (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74,49-129[Medline]
  82. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., Ahn, N. G. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265,966-970[Abstract/Free Full Text]
  83. Cowley, S., Paterson, H., Kemp, P., Marshall, C. J. (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77,841-852[Medline]
  84. Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., Yoshida, O. (1995) Constitutive activation of mitogen- activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55,4182-4187[Abstract/Free Full Text]
  85. Sivaraman, V., Wang, H., Nuovo, G., Malbon, C. (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99,1478-1483[Medline]
  86. Khosravi-Far, R., Campbell, S., Rossman, K. L., Der, C. J. (1998) Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv. Cancer Res. 72,57-107[Medline]
  87. Leppä, S., Saffrich, R., Ansorge, W., Bohmann, D. (1998) Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J 17,4404-4413[Medline]
  88. Price, M. A., Cruzalegui, F. H., Treisman, R. (1996) The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. EMBO J 15,6552-6563[Medline]
  89. O'Hagan, R. C., Tozer, R. G., Symons, M., McCormick, F., Hassell, J. A. (1996) The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 13,1323-1333[Medline]
  90. Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J., Davis, R. J. (1998) A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281,1671-1674[Abstract/Free Full Text]
  91. Schaeffer, H. J., Catling, A. D., Eblen, S. T., Collier, L. S., Krauss, A., Weber, M. J. (1998) MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281,1668-1671[Abstract/Free Full Text]
  92. Kim, S. J., Lafyatis, R., Kim, K. Y., Angel, P., Fujiki, H., Karin, M., Sporn, M. B., Roberts, A. B. (1990) Regulation of collagenase gene expression by okadaic acid, an inhibitor of protein phosphatases. Cell Regul 1,269-278[Medline]
  93. Frost, J. A., Geppert, T. D., Cobb, M. H., Feramisco, J. R. (1994) A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha- Ras, phorbol 12-myristate 13-acetate, and serum. Proc. Natl. Acad. Sci. U. S. A. 91,3844-3848[Abstract/Free Full Text]
  94. Rutter, G. A., White, M. R., Tavare, J. M. (1995) Involvement of MAP kinase in insulin signalling revealed by non-invasive imaging of luciferase gene expression in single living cells. Curr. Biol. 5,890-899[Medline]
  95. Korzus, E., Nagase, H., Rydell, R., Travis, J. (1997) The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M- responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J. Biol. Chem. 272,1188-1196[Abstract/Free Full Text]
  96. Reifel-Miller, A. E., Conarty, D. M., Valasek, K. M., Iversen, P. W., Burns, D. J., Birch, K. A. (1996) Protein kinase C isozymes differentially regulate promoters containing PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs. J. Biol. Chem. 271,21666-21671[Abstract/Free Full Text]
  97. Reunanen, N., Westermarck, J., Häkkinen, L., Holmström, T. H., Elo, I., Eriksson, J. E., Kähäri, V.-M. (1998) Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J. Biol. Chem. 273,5137-5145[Abstract/Free Full Text]
  98. Westermarck, J., Holmström, T. H., Ahonen, M., Eriksson, J. E., Kähäri, V.-M. (1998) Enhancement of collagenase-1–1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38. Matrix Biol 17,547-557[Medline]
  99. Ridley, S. H., Sarsfield, S. J., Lee, J. C., Bigg, H. F., Cawston, T. E., Taylor, D. J., DeWitt, D. L., Saklatvala, J. (1997) Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J. Immunol. 158,3165-3173[Abstract]
  100. Ravanti, L., Heino, J., López-Otín, C., Kähäri, V.-M. (1999) Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. 274,2446-2455[Abstract/Free Full Text]
  101. Gum, R., Wang, H., Lengyel, E., Juarez, J., Boyd, D. (1997) Regulation of 92 kDa type IV collagenase expression of the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 14,1481-1493[Medline]
  102. Simon, C., Goepfert, H., Boyd, D. (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 58,1135-1139[Abstract/Free Full Text]
  103. Holmström, T. H., Chow, S. C., Elo, I., Coffey, E. T., Orrenius, S., Sistonen, L., Eriksson, J. E. (1998) Suppression of Fas/APO-1-mediated apoptosis by mitogen- activated kinase signaling. J. Immunol. 160,2626-2636[Abstract/Free Full Text]
  104. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., Greenberg, M. E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270,1326-1331[Abstract/Free Full Text]
  105. Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., Akhurst, R. J. (1996) TGF-ß1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86,531-542[Medline]
  106. Westermarck, J., Häkkinen, L., Fiers, W., Kähäri, V.-M. (1995) TNF-R55- specific form of human tumor necrosis factor-{alpha} induces collagenase gene expression by human skin fibroblasts. J. Invest. Dermatol. 105,197-202[Medline]
  107. Pender, S., Fell, J., Chamow, S., Ashkenazi, A., MacDonald, T. (1998) A p55 TNF receptor immunoadhesion prevents T cell-mediated intenstinal injury by inhibiting matrix metalloproteinase production. J. Immunol. 160,4098-4103[Abstract/Free Full Text]
  108. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2,668-675[Medline]
  109. Shiozawa, S., Shimizu, K., Tanaka, K., Hino, K. (1997) Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin. Invest. 99,1210-1216[Medline]
  110. Huang, C., Ma, W. Y., Dawson, M. I., Rincon, M., Flavell, R. A., Dong, Z. (1997) Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl. Acad. Sci. U. S. A. 94,5826-5830[Abstract/Free Full Text]
  111. Hua, J., Muschel, R. J. (1996) Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56,5279-5284[Abstract/Free Full Text]
  112. Hasegawa, S., Koshikawa, N., Momiyama, N., Moriyama, K., Ichikawa, Y., Ishikawa, T., Mitsuhashi, M., Shimada, H., Miyazaki, K. (1998) Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer 76,812-816[Medline]
  113. Brown, P. D. (1998) Synthetic inhibitors of matrix metalloproteinases. Parks, W. C. Mecham, R. P. eds. Matrix Metalloproteinases ,243-262
  114. Kähäri, V.-M., Saarialho-Kere, U. (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann. Med. 31,34-45[Medline]
  115. Fife, R. S., Rougraff, B. T., Proctor, C., Sledge, G. W., Jr (1997) Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J. Lab. Clin. Med. 130,530-534[Medline]



This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
K. Itatsu, M. Sasaki, J. Yamaguchi, S. Ohira, A. Ishikawa, H. Ikeda, Y. Sato, K. Harada, Y. Zen, H. Sato, et al.
Cyclooxygenase-2 Is Involved in the Up-Regulation of Matrix Metalloproteinase-9 in Cholangiocarcinoma Induced by Tumor Necrosis Factor-{alpha}
Am. J. Pathol., March 1, 2009; 174(3): 829 - 841.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Song, Y. Li, J. Lee, A. L. Schwartz, and G. Bu
Low-Density Lipoprotein Receptor-Related Protein 1 Promotes Cancer Cell Migration and Invasion by Inducing the Expression of Matrix Metalloproteinases 2 and 9
Cancer Res., February 1, 2009; 69(3): 879 - 886.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J.-A. Liang, S.-L. Wu, H.-Y. Lo, C.-Y. Hsiang, and T.-Y. Ho
Vanillin Inhibits Matrix Metalloproteinase-9 Expression through Down-Regulation of Nuclear Factor-{kappa}B Signaling Pathway in Human Hepatocellular Carcinoma Cells
Mol. Pharmacol., January 1, 2009; 75(1): 151 - 157.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J.-H. Chen, H.-H. Lin, T.-A. Chiang, J.-D. Hsu, H.-H. Ho, Y.-C. Lee, and C.-J. Wang
Gaseous Nitrogen Oxide Promotes Human Lung Cancer Cell Line A549 Migration, Invasion, and Metastasis via iNOS-Mediated MMP-2 Production
Toxicol. Sci., December 1, 2008; 106(2): 364 - 375.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. H. Ho, T. T. Antoniv, J.-D. Ji, and L. B. Ivashkiv
Lipopolysaccharide-Induced Expression of Matrix Metalloproteinases in Human Monocytes Is Suppressed by IFN-{gamma} via Superinduction of ATF-3 and Suppression of AP-1
J. Immunol., October 1, 2008; 181(7): 5089 - 5097.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
E. Ispanovic, D. Serio, and T. L. Haas
Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation
Am J Physiol Cell Physiol, September 1, 2008; 295(3): C600 - C610.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
N. Lu, Y. Ling, Y. Gao, Y. Chen, R. Mu, Q. Qi, W. Liu, H. Zhang, H. Gu, S. Wang, et al.
Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells
Experimental Biology and Medicine, August 1, 2008; 233(8): 1013 - 1020.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
C. J. Lockwood, C. Oner, Y. H. Uz, U. A. Kayisli, S. J. Huang, L. F. Buchwalder, W. Murk, E. F. Funai, and F. Schatz
Matrix Metalloproteinase 9 (MMP9) Expression in Preeclamptic Decidua and MMP9 Induction by Tumor Necrosis Factor Alpha and Interleukin 1 Beta in Human First Trimester Decidual Cells
Biol Reprod, June 1, 2008; 78(6): 1064 - 1072.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C.-J. Weng, C.-F. Chau, Y.-S. Hsieh, S.-F. Yang, and G.-C. Yen
Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-{kappa}B and AP-1
Carcinogenesis, January 1, 2008; 29(1): 147 - 156.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. A. Jones, R. E. Stroud, B. S. Kaplan, A. M. Leone, J. E. Bavaria, J. H. Gorman III, R. C. Gorman, and J. S. Ikonomidis
Differential Protein Kinase C Isoform Abundance in Ascending Aortic Aneurysms From Patients With Bicuspid Versus Tricuspid Aortic Valves
Circulation, September 11, 2007; 116(11_suppl): I-144 - I-149.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
C. Guruvayoorappan and G. Kuttan
{beta}-Carotene Inhibits Tumor-Specific Angiogenesis by Altering the Cytokine Profile and Inhibits the Nuclear Translocation of Transcription Factors in B16F-10 Melanoma Cells
Integr Cancer Ther, September 1, 2007; 6(3): 258 - 270.
[Abstract] [PDF]


Home page
Cancer Res.Home page
M. Monge, E. Colas, A. Doll, M. Gonzalez, A. Gil-Moreno, J. Planaguma, M. Quiles, M. A. Arbos, A. Garcia, J. Castellvi, et al.
ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer
Cancer Res., July 15, 2007; 67(14): 6753 - 6759.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
C. Guruvayoorappan and G. Kuttan
Effect of Amentoflavone on the Inhibition of Pulmonary Metastasis Induced by B16F-10 Melanoma Cells in C57BL/6 Mice
Integr Cancer Ther, June 1, 2007; 6(2): 185 - 197.
[Abstract] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Simsa, A. Hasdai, H. Dan, and E. M. Ornan
Differential regulation of MMPs and matrix assembly in chicken and turkey growth-plate chondrocytes
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2216 - R2224.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Y.-S. Hsieh, S.-C. Chu, S.-F. Yang, P.-N. Chen, Y.-C. Liu, and K.-H. Lu
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2
Carcinogenesis, May 1, 2007; 28(5): 977 - 987.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Ries, V. Egea, M. Karow, H. Kolb, M. Jochum, and P. Neth
MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines
Blood, May 1, 2007; 109(9): 4055 - 4063.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F.-C. Ye, D. J. Blackbourn, M. Mengel, J.-P. Xie, L.-W. Qian, W. Greene, I-T. Yeh, D. Graham, and S.-J. Gao
Kaposi's Sarcoma-Associated Herpesvirus Promotes Angiogenesis by Inducing Angiopoietin-2 Expression via AP-1 and Ets1
J. Virol., April 15, 2007; 81(8): 3980 - 3991.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Hulit, K. Suyama, S. Chung, R. Keren, G. Agiostratidou, W. Shan, X. Dong, T. M. Williams, M. P. Lisanti, K. Knudsen, et al.
N-Cadherin Signaling Potentiates Mammary Tumor Metastasis via Enhanced Extracellular Signal-Regulated Kinase Activation
Cancer Res., April 1, 2007; 67(7): 3106 - 3116.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J.-M. Park, A. Kim, J.-H. Oh, and A.-S. Chung
Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-{kappa}B activation
Carcinogenesis, April 1, 2007; 28(4): 837 - 847.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Johannsson, T. Henriksen, and P. O. Iversen
Increase in matrix metalloproteinases from endothelial cells exposed to umbilical cord plasma from high birth weight newborns
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1563 - R1568.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
D. J. H. Mountain, M. Singh, B. Menon, and K. Singh
Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKC{alpha}/beta1 and MAPKs
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C867 - C875.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Onai, J.-i. Suzuki, Y. Maejima, G. Haraguchi, S. Muto, A. Itai, and M. Isobe
Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H530 - H538.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H.-J. Byun, I.-K. Hong, E. Kim, Y.-J. Jin, D.-I. Jeoung, J.-H. Hahn, Y.-M. Kim, S. H. Park, and H. Lee
A Splice Variant of CD99 Increases Motility and MMP-9 Expression of Human Breast Cancer Cells through the AKT-, ERK-, and JNK-dependent AP-1 Activation Signaling Pathways
J. Biol. Chem., November 17, 2006; 281(46): 34833 - 34847.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S.-O. Yoon, S. Shin, H.-J. Lee, H.-K. Chun, and A.-S. Chung
Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression.
Mol. Cancer Ther., November 1, 2006; 5(11): 2666 - 2675.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Kroczynska, R. Cutrone, M. Bocchetta, H. Yang, A. G. Elmishad, P. Vacek, M. Ramos-Nino, B. T. Mossman, H. I. Pass, and M. Carbone
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters
PNAS, September 19, 2006; 103(38): 14128 - 14133.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Kishi, S. Okudaira, M. Tanaka, K. Hama, D. Shida, J. Kitayama, T. Yamori, J. Aoki, T. Fujimaki, and H. Arai
Autotaxin Is Overexpressed in Glioblastoma Multiforme and Contributes to Cell Motility of Glioblastoma by Converting Lysophosphatidylcholine TO Lysophosphatidic Acid
J. Biol. Chem., June 23, 2006; 281(25): 17492 - 17500.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub
Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility
J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Y. Eum, Y. W. Lee, B. Hennig, and M. Toborek
Interplay between Epidermal Growth Factor Receptor and Janus Kinase 3 Regulates Polychlorinated Biphenyl-Induced Matrix Metalloproteinase-3 Expression and Transendothelial Migration of Tumor Cells
Mol. Cancer Res., June 1, 2006; 4(6): 361 - 370.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. K. Nelson, S. Subbaram, K. M. Connor, J. Dasgupta, X.-F. Ha, T.-C. Meng, N. K. Tonks, and J. A. Melendez
Redox-dependent Matrix Metalloproteinase-1 Expression Is Regulated by JNK through Ets and AP-1 Promoter Motifs
J. Biol. Chem., May 19, 2006; 281(20): 14100 - 14110.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Shukla, T. F. Barrett, K. I. Nakayama, K. Nakayama, B. T. Mossman, and K. M. Lounsbury
Transcriptional up-regulation of MMP12 and MMP13 by asbestos occurs via a PKC{delta}-dependent pathway in murine lung
FASEB J, May 1, 2006; 20(7): 997 - 999.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
P.-N. Chen, Y.-S. Hsieh, C.-L. Chiang, H.-L. Chiou, S.-F. Yang, and S.-C. Chu
Silibinin Inhibits Invasion of Oral Cancer Cells by Suppressing the MAPK Pathway
Journal of Dental Research, March 1, 2006; 85(3): 220 - 225.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. M. Deschamps and F. G. Spinale
Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation
Cardiovasc Res, February 15, 2006; 69(3): 666 - 676.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Xie, H. Pan, S. Yoo, and S.-J. Gao
Kaposi's Sarcoma-Associated Herpesvirus Induction of AP-1 and Interleukin 6 during Primary Infection Mediated by Multiple Mitogen-Activated Protein Kinase Pathways
J. Virol., December 15, 2005; 79(24): 15027 - 15037.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Behren, C. Simon, R. M. Schwab, E. Loetzsch, S. Brodbeck, E. Huber, F. Stubenrauch, H. P. Zenner, and T. Iftner
Papillomavirus E2 Protein Induces Expression of the Matrix Metalloproteinase-9 via the Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Pathway
Cancer Res., December 15, 2005; 65(24): 11613 - 11621.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. K. Mantena, S. M. Meeran, C. A. Elmets, and S. K. Katiyar
Orally Administered Green Tea Polyphenols Prevent Ultraviolet Radiation-Induced Skin Cancer in Mice through Activation of Cytotoxic T Cells and Inhibition of Angiogenesis in Tumors
J. Nutr., December 1, 2005; 135(12): 2871 - 2877.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. G. Lee, S. Dahi, R. Mahimkar, N. L. Tulloch, M. A. Alfonso-Jaume, D. H. Lovett, and R. Sarkar
Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia
PNAS, November 8, 2005; 102(45): 16345 - 16350.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
E. Elass, L. Aubry, M. Masson, A. Denys, Y. Guerardel, E. Maes, D. Legrand, J. Mazurier, and L. Kremer
Mycobacterial Lipomannan Induces Matrix Metalloproteinase-9 Expression in Human Macrophagic Cells through a Toll-Like Receptor 1 (TLR1)/TLR2- and CD14-Dependent Mechanism
Infect. Immun., October 1, 2005; 73(10): 7064 - 7068.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D. A. Kuppers, K. Lan, J. S. Knight, and E. S. Robertson
Regulation of Matrix Metalloproteinase 9 Expression by Epstein-Barr Virus Nuclear Antigen 3C and the Suppressor of Metastasis Nm23-H1
J. Virol., August 1, 2005; 79(15): 9714 - 9724.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Choi, K. Choi, E. N. Benveniste, Y.-S. Hong, J.-H. Lee, J. Kim, and K. Park
Bcl-2 Promotes Invasion and Lung Metastasis by Inducing Matrix Metalloproteinase-2
Cancer Res., July 1, 2005; 65(13): 5554 - 5560.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Jinnin, H. Ihn, Y. Mimura, Y. Asano, K. Yamane, and K. Tamaki
Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1
Nucleic Acids Res., June 21, 2005; 33(11): 3540 - 3549.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Reich, Y. Katz, R. Hadar, and E. Breuer
Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 3: In vivo Evaluation of Cyclopentylcarbamoylphosphonic Acid in Experimental Metastasis and Angiogenesis
Clin. Cancer Res., May 15, 2005; 11(10): 3925 - 3929.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. Duca, E. Lambert, R. Debret, B. Rothhut, C. Blanchevoye, F. Delacoux, W. Hornebeck, L. Martiny, and L. Debelle
Elastin Peptides Activate Extracellular Signal-Regulated Kinase 1/2 via a Ras-Independent Mechanism Requiring Both p110{gamma}/Raf-1 and Protein Kinase A/B-Raf Signaling in Human Skin Fibroblasts
Mol. Pharmacol., April 1, 2005; 67(4): 1315 - 1324.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
V. Iyer, K. Pumiglia, and C. M. DiPersio
{alpha}3{beta}1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression
J. Cell Sci., March 15, 2005; 118(6): 1185 - 1195.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. M. Kauppinen and R. A. Swanson
Poly(ADP-Ribose) Polymerase-1 Promotes Microglial Activation, Proliferation, and Matrix Metalloproteinase-9-Mediated Neuron Death
J. Immunol., February 15, 2005; 174(4): 2288 - 2296.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. S. Deshmukh, L. M. Case, S. C. Wesselkamper, M. T. Borchers, L. D. Martin, H. G. Shertzer, J. A. Nadel, and G. D. Leikauf
Metalloproteinases Mediate Mucin 5AC Expression by Epidermal Growth Factor Receptor Activation
Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 305 - 314.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H.-S. Hofmann, G. Hansen, G. Richter, C. Taege, A. Simm, R.-E. Silber, and S. Burdach
Matrix Metalloproteinase-12 Expression Correlates with Local Recurrence and Metastatic Disease in Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 1, 2005; 11(3): 1086 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Perissinotto, G. Cavalloni, F. Leone, V. Fonsato, S. Mitola, G. Grignani, N. Surrenti, D. Sangiolo, F. Bussolino, W. Piacibello, et al.
Involvement of Chemokine Receptor 4/Stromal Cell-Derived Factor 1 System during Osteosarcoma Tumor Progression
Clin. Cancer Res., January 15, 2005; 11(2): 490 - 497.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Louis, N. Guerineau, O. Fromigue, V. Defamie, A. Collazos, P. Anglard, M. A. Shipp, P. Auberger, D. Joubert, and B. Mari
Tumor Cell-mediated Induction of the Stromal Factor Stromelysin-3 Requires Heterotypic Cell Contact-dependent Activation of Specific Protein Kinase C Isoforms
J. Biol. Chem., January 14, 2005; 280(2): 1272 - 1283.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E.-M. Schnaeker, R. Ossig, T. Ludwig, R. Dreier, H. Oberleithner, M. Wilhelmi, and S. W. Schneider
Microtubule-Dependent Matrix Metalloproteinase-2/Matrix Metalloproteinase-9 Exocytosis: Prerequisite in Human Melanoma Cell Invasion
Cancer Res., December 15, 2004; 64(24): 8924 - 8931.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-H. Woo, J.-H. Lim, and J.-H. Kim
Lipopolysaccharide Induces Matrix Metalloproteinase-9 Expression via a Mitochondrial Reactive Oxygen Species-p38 Kinase-Activator Protein-1 Pathway in Raw 264.7 Cells
J. Immunol., December 1, 2004; 173(11): 6973 - 6980.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. G. Lechuga, Z. H. Hernandez-Nazara, J.-A. D. Rosales, E. R. Morris, A. R. Rincon, A. M. Rivas-Estilla, A. Esteban-Gamboa, and M. Rojkind
TGF-{beta}1 modulates matrix metalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK, PI3-kinase, AKT, and p70S6k
Am J Physiol Gastrointest Liver Physiol, November 1, 2004; 287(5): G974 - G987.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Mori, M. Shibanuma, and K. Nose
Invasive Potential Induced under Long-Term Oxidative Stress in Mammary Epithelial Cells
Cancer Res., October 15, 2004; 64(20): 7464 - 7472.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Ezashi and R. M. Roberts
Regulation of Interferon-{tau} (IFN-{tau}) Gene Promoters by Growth Factors that Target the Ets-2 Composite Enhancer: A Possible Model for Maternal Control of IFN-{tau} Production by the Conceptus during Early Pregnancy
Endocrinology, October 1, 2004; 145(10): 4452 - 4460.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Xie, M. Singh, and K. Singh
Differential Regulation of Matrix Metalloproteinase-2 and -9 Expression and Activity in Adult Rat Cardiac Fibroblasts in Response to Interleukin-1{beta}
J. Biol. Chem., September 17, 2004; 279(38): 39513 - 39519.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dona, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, M. D. Barbera, A. Donella-Deana, G. Appendino, A. Borsarini, R. Caniato, et al.
Hyperforin Inhibits Cancer Invasion and Metastasis
Cancer Res., September 1, 2004; 64(17): 6225 - 6232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. A. Mitchell, O. Shynlova, B. L. Langille, and S. J. Lye
Mechanical stretch and progesterone differentially regulate activator protein-1 transcription factors in primary rat myometrial smooth muscle cells
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E439 - E445.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. T. Huntington, J. M. Shields, C. J. Der, C. A. Wyatt, U. Benbow, C. L. Slingluff Jr., and C. E. Brinckerhoff
Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells: ROLE OF BRAF MUTATION AND FIBROBLAST GROWTH FACTOR SIGNALING
J. Biol. Chem., August 6, 2004; 279(32): 33168 - 33176.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Hagemann, S. C. Robinson, M. Schulz, L. Trumper, F. R. Balkwill, and C. Binder
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-{alpha} dependent up-regulation of matrix metalloproteases
Carcinogenesis, August 1, 2004; 25(8): 1543 - 1549.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Miyata, T. Sato, M. Yano, and A. Ito
Activation of protein kinase C {beta}II/{varepsilon}-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin
Mol. Cancer Ther., July 1, 2004; 3(7): 839 - 847.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
T T L Wong, J T Daniels, J G Crowston, and P T Khaw
MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule
Br. J. Ophthalmol., July 1, 2004; 88(7): 868 - 872.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Selvamurugan, S. Kwok, and N. C. Partridge
Smad3 Interacts with JunB and Cbfa1/Runx2 for Transforming Growth Factor-{beta}1-stimulated Collagenase-3 Expression in Human Breast Cancer Cells
J. Biol. Chem., June 25, 2004; 279(26): 27764 - 27773.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. K. Vayalil, A. Mittal, and S. K. Katiyar
Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF{kappa}B
Carcinogenesis, June 1, 2004; 25(6): 987 - 995.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Givant-Horwitz, B. Davidson, and R. Reich
Laminin-Induced Signaling in Tumor Cells: The Role of the Mr 67,000 Laminin Receptor
Cancer Res., May 15, 2004; 64(10): 3572 - 3579.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. G. Phillips and L. M. Birnby
Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface
Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L1055 - L1065.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. A. Scott, J. K. Vass, E. K. Parkinson, D. A. F. Gillespie, J. N. Winnie, and B. W. Ozanne
Invasion of Normal Human Fibroblasts Induced by v-Fos Is Independent of Proliferation, Immortalization, and the Tumor Suppressors p16INK4a and p53
Mol. Cell. Biol., February 15, 2004; 24(4): 1540 - 1559.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. P. Jansen, C. E. Camalier, C. Stark, and N. H. Colburn
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
Mol. Cancer Ther., February 1, 2004; 3(2): 103 - 110.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Leppa, T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa
A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma
Clin. Cancer Res., February 1, 2004; 10(3): 1057 - 1063.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
A. S. Ulku, R. Schafer, and C. J. Der
Essential Role of Raf in Ras Transformation and Deregulation of Matrix Metalloproteinase Expression in Ovarian Epithelial Cells
Mol. Cancer Res., December 1, 2003; 1(14): 1077 - 1088.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Roelle, R. Grosse, A. Aigner, H. W. Krell, F. Czubayko, and T. Gudermann
Matrix Metalloproteinases 2 and 9 Mediate Epidermal Growth Factor Receptor Transactivation by Gonadotropin-releasing Hormone
J. Biol. Chem., November 21, 2003; 278(47): 47307 - 47318.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. L. Dai, N. Makretsov, E. I. Campos, C. Huang, Y. Zhou, D. Huntsman, M. Martinka, and G. Li
Increased Expression of Integrin-Linked Kinase Is Correlated with Melanoma Progression and Poor Patient Survival
Clin. Cancer Res., October 1, 2003; 9(12): 4409 - 4414.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Liao, J. C. Wolfman, and A. Wolfman
K-Ras Regulates the Steady-state Expression of Matrix Metalloproteinase 2 in Fibroblasts
J. Biol. Chem., August 22, 2003; 278(34): 31871 - 31878.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
E. Mazzoni, A. Adam, E. Bal de Kier Joffe, and J. A. Aguirre-Ghiso
Immortalized Mammary Epithelial Cells Overexpressing Protein Kinase C {gamma} Acquire a Malignant Phenotype and Become Tumorigenic in Vivo
Mol. Cancer Res., August 1, 2003; 1(10): 776 - 787.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. Luparello, R. Sirchia, and D. Pupello
PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression
J. Cell Sci., June 15, 2003; 116(12): 2421 - 2430.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. M. Mason and N. A. Wahab
Extracellular Matrix Metabolism in Diabetic Nephropathy
J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-M. Maula, M. Luukkaa, R. Grenman, D. Jackson, S. Jalkanen, and R. Ristamaki
Intratumoral Lymphatics Are Essential for the Metastatic Spread and Prognosis in Squamous Cell Carcinomas of the Head and Neck Region
Cancer Res., April 15, 2003; 63(8): 1920 - 1926.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. H. Wilson, A. V. Ljubimov, A. O. Morla, S. Caballero, L. C. Shaw, P. E. Spoerri, R. W. Tarnuzzer, and M. B. Grant
Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation through {alpha}5{beta}1 Integrin and PI 3-Kinase
Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1704 - 1715.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. T. L. Wong, A. L. Mead, and P. T. Khaw
Matrix Metalloproteinase Inhibition Modulates Postoperative Scarring after Experimental Glaucoma Filtration Surgery
Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1097 - 1103.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Kast, M. Wang, and M. Whiteway
The ERK/MAPK Pathway Regulates the Activity of the Human Tissue Factor Pathway Inhibitor-2 Promoter
J. Biol. Chem., February 21, 2003; 278(9): 6787 - 6794.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Razandi, A. Pedram, S. T. Park, and E. R. Levin
Proximal Events in Signaling by Plasma Membrane Estrogen Receptors
J. Biol. Chem., January 17, 2003; 278(4): 2701 - 2712.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. K. Nelson, A. C. Ranganathan, J. Mansouri, A. M. Rodriguez, K. M. Providence, J. L. Rutter, K. Pumiglia, J. A. Bennett, and J. A. Melendez
Elevated Sod2 Activity Augments Matrix Metalloproteinase Expression: Evidence for the Involvement of Endogenous Hydrogen Peroxide in Regulating Metastasis
Clin. Cancer Res., January 1, 2003; 9(1): 424 - 432.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Varani, P. Perone, M. G. Merfert, S. E. Moon, D. Larkin, and M. J. Stevens
All-trans Retinoic Acid Improves Structure and Function of Diabetic Rat Skin in Organ Culture
Diabetes, December 1, 2002; 51(12): 3510 - 3516.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. A. Benanti, D. K. Williams, K. L. Robinson, H. L. Ozer, and D. A. Galloway
Induction of Extracellular Matrix-Remodeling Genes by the Senescence-Associated Protein APA-1
Mol. Cell. Biol., November 1, 2002; 22(21): 7385 - 7397.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. W. Spurbeck, C. Y. C. Ng, T. S. Strom, E. F. Vanin, and A. M. Davidoff
Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model
Blood, October 16, 2002; 100(9): 3361 - 3368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. G. Munshi, S. Ghosh, S. Mukhopadhyay, Y. I. Wu, R. Sen, K. J. Green, and M. S. Stack
Proteinase Suppression by E-cadherin-mediated Cell-Cell Attachment in Premalignant Oral Keratinocytes
J. Biol. Chem., October 4, 2002; 277(41): 38159 - 38167.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Reunanen, S.-P. Li, M. Ahonen, M. Foschi, J. Han, and V.-M. Kahari
Activation of p38alpha MAPK Enhances Collagenase-1 (Matrix Metalloproteinase (MMP)-1) and Stromelysin-1 (MMP-3) Expression by mRNA Stabilization
J. Biol. Chem., August 23, 2002; 277(35): 32360 - 32368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Park, Y. Kim, Y. Lim, I. Han, and E.-S. Oh
Syndecan-2 Mediates Adhesion and Proliferation of Colon Carcinoma Cells
J. Biol. Chem., August 9, 2002; 277(33): 29730 - 29736.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-O. Yoon, S.-J. Park, S. Y. Yoon, C.-H. Yun, and A.-S. Chung
Sustained Production of H2O2 Activates Pro-matrix Metalloproteinase-2 through Receptor Tyrosine Kinases/Phosphatidylinositol 3-Kinase/NF-kappa B Pathway
J. Biol. Chem., August 9, 2002; 277(33): 30271 - 30282.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Bloomston, E. E. Zervos, and A. S. Rosemurgy II
Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials
Ann. Surg. Oncol., August 1, 2002; 9(7): 668 - 674.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. Ludwig, R. Ossig, S. Graessel, M. Wilhelmi, H. Oberleithner, and S. W. Schneider
The electrical resistance breakdown assay determines the role of proteinases in tumor cell invasion
Am J Physiol Renal Physiol, August 1, 2002; 283(2): F319 - F327.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
J. A. Mitchell and S. J. Lye
Differential Expression of Activator Protein-1 Transcription Factors in Pregnant Rat Myometrium
Biol Reprod, July 1, 2002; 67(1): 240 - 246.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Reisdorff, A. En-Nia, I. Stefanidis, J. Floege, D. H. Lovett, and P. R. Mertens
Transcription Factor Ets-1 Regulates Gelatinase A Gene Expression in Mesangial Cells
J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1568 - 1578.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. V. Tsytsykova and A. E. Goldfeld
Inducer-Specific Enhanceosome Formation Controls Tumor Necrosis Factor Alpha Gene Expression in T Lymphocytes
Mol. Cell. Biol., April 15, 2002; 22(8): 2620 - 2631.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Min, A. G. Moore, M. A. Bain, S. N. Breit, and J. G. Lyons
Activation of Macrophage Promatrix Metalloproteinase-9 by Lipopolysaccharide-Associated Proteinases
J. Immunol., March 1, 2002; 168(5): 2449 - 2455.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Sato, L. Koike, Y. Miyata, M. Hirata, Y. Mimaki, Y. Sashida, M. Yano, and A. Ito
Inhibition of Activator Protein-1 Binding Activity and Phosphatidylinositol 3-Kinase Pathway by Nobiletin, a Polymethoxy Flavonoid, Results in Augmentation of Tissue Inhibitor of Metalloproteinases-1 Production and Suppression of Production of Matrix Metalloproteinases-1 and -9 in Human Fibrosarcoma HT-1080 Cells
Cancer Res., February 1, 2002; 62(4): 1025 - 1029.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann
Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?
Oncologist, February 1, 2002; 7(1): 17 - 33.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Oelmann, H. Herbst, M. Zuhlsdorf, O. Albrecht, A. Nolte, C. Schmitmann, O. Manzke, V. Diehl, H. Stein, and W. E. Berdel
Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells
Blood, January 1, 2002; 99(1): 258 - 267.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Engers, E. Springer, F. Michiels, J. G. Collard, and H. E. Gabbert
Rac Affects Invasion of Human Renal Cell Carcinomas by Up-regulating Tissue Inhibitor of Metalloproteinases (TIMP)-1 and TIMP-2 Expression
J. Biol. Chem., November 2, 2001; 276(45): 41889 - 41897.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Asahi, X. Wang, T. Mori, T. Sumii, J.-C. Jung, M. A. Moskowitz, M. E. Fini, and E. H. Lo
Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood-Brain Barrier and White Matter Components after Cerebral Ischemia
J. Neurosci., October 1, 2001; 21(19): 7724 - 7732.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WESTERMARCK, J.
Right arrow Articles by KÄHÄRI, V.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WESTERMARCK, J.
Right arrow Articles by KÄHÄRI, V.-M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS